摘要
随着小分子疗法及各类生物制剂的不断研发,支气管哮喘的治疗获得革命性突破,然而对于部分发病机制复杂的难治性哮喘患者,其发病机制与治疗仍是临床研究的热点和难点。难治性哮喘的传统用药包括症状控制性用药(缓释茶碱、白三烯调节剂等)和症状缓解性用药(糖皮质激素、短效茶碱等),新型用药以免疫抑制剂、生物制剂等较为常见,各类药物均有其优缺点,针对部分病情较为严重的患者还可采用多药联合使用的方法。但疾病具体的药物治疗方案与标准仍未统一,还需要未来进行深入的研究。
With the continuous development of small molecule therapy and various biological agents,the treatment of bronchial asthma has made a revolutionary breakthrough.However,for some patients with refractory asthma with complicated pathogenesis,its pathogenesis and treatment are still hotspots and difficult issues in the clinical practice.Traditional medications for refractory asthma include symptom-controlled medication(sustained release of theophylline,leukotriene modifiers,etc.),and symptom-palliative medication(glucocorticoids,short-acting theophylline,etc.).New drugs are mostly immunosuppressive agents,biological agents,etc.The application of each drug has its advantages and disadvantages,which can also be used in combination with multiple drugs for the patients with relatively serious conditions.However,the specific drug treatment programs and standards are still not unified,and more in-depth research is needed in the future.
作者
李芳学
刘娟
LI Fangxue;LIU Juan(Department of Respiratory Medicine,China University of Petroleum(Eastern China)Hospital,Qingdao 266580,China;Department of Preventive Health Care,Dongying City Shengli Oilfield Central Hospital,Dongying 257034,China)
出处
《医学综述》
2020年第8期1573-1577,共5页
Medical Recapitulate
关键词
支气管哮喘
难治性支气管哮喘
作用机制
Bronchial asthma
Refractory bronchial asthma
Mechanism of action
